Skip to main content

Research Repository

See what's under the surface

Advanced Search

Minocycline hepatotoxicity: clinical characterization and identification of HLA-B∗ 35:02 as a risk factor

Urban, Thomas Jacob; Nicoletti, Paola; Chalasani, Naga; Serrano, Jose; Stolz, Andrew; Daly, Ann K.; Aithal, Guruprasad P.; Dillon, John F.; Navarro, Victor; Odin, Joseph; Barnhart, Huiman X.; Ostrov, David; Long, Nanye; Cirulli, Elizabeth Theresa; Watkins, Paul Brent; Fontana, Robert John

Authors

Thomas Jacob Urban

Paola Nicoletti

Naga Chalasani

Jose Serrano

Andrew Stolz

Ann K. Daly

Guruprasad P. Aithal

John F. Dillon

Victor Navarro

Joseph Odin

Huiman X. Barnhart

David Ostrov

Nanye Long

Elizabeth Theresa Cirulli

Paul Brent Watkins

Robert John Fontana



Abstract

Minocycline hepatotoxicity can present with prominent autoimmune features in previously healthy individuals. The aim of this study was to identify genetic determinants of minocycline DILI in a well-phenotyped cohort of patients. Methods: Caucasian patients with minocycline DILI underwent genome-wide genotyping and were compared to unexposed population controls. Human leukocyte antigen (HLA) binding of minocycline was assessed using AutoDock Vina. Results: Amongst the 25 cases, 80% were female, median age was 19 years and median latency from drug start to DILI onset was 318 days. At presentation, 76% had acute hepatocellular liver injury, median ALT 1077 U/L (range: 63 to 2333), median bilirubin 4.5 mg/dl (range: 0.2 to 16.7), and 90% had a +ANA. During follow-up, 50% were treated with corticosteroids and no subjects died or required a liver transplant. A significant association was noted between HLA-B∗35:02 and risk for minocycline-DILI; a 16% carrier frequency in DILI cases compared to 0.6% in population controls (Odds Ratio: 29.6, 95% CI: 7.8-89.8, p=2.5 x 10-8). Verification of HLA-B∗35:02 imputation was confirmed by sequence-based HLA typing. HLA-B∗35:02 carriers had similar presenting features and outcomes compared to non-carriers. In silico modeling studies support the hypothesis that direct binding of minocycline to this novel HLA risk allele might be an important initiating event in minocycline-DILI. Conclusion: HLA-B∗35:02 is a rare HLA allele that was more frequently identified in the 25 minocycline-DILI cases compared to population controls. If confirmed in other cohorts, this HLA allele may prove to be a useful diagnostic marker of minocycline DILI.

Journal Article Type Article
Journal Journal of Hepatology
Print ISSN 0168-8278
Electronic ISSN 1600-0641
Publisher Elsevier
Peer Reviewed Peer Reviewed
Volume 67
Issue 1
Pages 137-144
APA6 Citation Urban, T. J., Nicoletti, P., Chalasani, N., Serrano, J., Stolz, A., Daly, A. K., …Fontana, R. J. (in press). Minocycline hepatotoxicity: clinical characterization and identification of HLA-B∗ 35:02 as a risk factor. Journal of Hepatology, 67(1), 137-144. doi:10.1016/j.jhep.2017.03.010
DOI https://doi.org/10.1016/j.jhep.2017.03.010
Keywords Drug induced liver injury, Single nucleotide polymorphism, Genetic association, Autoimmunity, Human leukocyte antigen
Publisher URL https://doi.org/10.1016/j.jhep.2017.03.010
Copyright Statement Copyright information regarding this work can be found at the following address: http://creativecommons.org/licenses/by-nc-nd/4.0

Files

Mino 1-s2.0-S0168827817301447-main.pdf (908 Kb)
PDF

Copyright Statement
Copyright information regarding this work can be found at the following address: http://creativecommons.org/licenses/by-nc-nd/4.0





You might also like



Downloadable Citations

;